Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: GlobeNewswire
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB). A live webcast of Ms. Ricciardi's presentation will be available on the Investor Relations section of Cognition’s website or by visiting: https://event.summitcast.com/view/cCMfZsH5ZqrwSNTwfC9JDv/e5J4Cq2iB2foBnz4AT3UbN. An archived replay of the presentation will be available for 90 days following the event. About Cognition Therapeutics: Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics CEO Issues Letter to Shareholders [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics CEO Issues Letter to ShareholdersGlobeNewswire
- Cognition Therapeutics (CGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $4.00 price target on the stock.MarketBeat
- Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateGlobeNewswire
CGTX
Earnings
- 5/7/25 - Miss
CGTX
Sec Filings
- 3/26/26 - Form S-8
- 3/26/26 - Form 10-K
- 3/26/26 - Form 8-K
- CGTX's page on the SEC website